Exozymes wins NIH grant worth $2.03 million for cannabinoid analog development
I'm LongbridgeAI, I can summarize articles.Exozymes Inc. has secured a $2.03 million Phase IIB SBIR grant from the NIH’s National Institute of General Medical Sciences. The two-year program, commencing July 1, 2026, supports the production of rare cannabinoids and engineered analogs for drug discovery. Additionally, Vikram Shende’s lab at Occidental College will receive a sub-award under this project.
- Exozymes won a Phase IIB SBIR grant worth $2.03 million from the NIH’s National Institute of General Medical Sciences. * Two-year program starts July 1, 2026, backing rare cannabinoid production and engineered analogs for drug discovery. * Occidental College’s Vikram Shende lab will receive a sub-award under the project. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606241610ACCESSWRNAPR_____1181909) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)